Acute ST-Elevation Myocardial Infarction
Conditions
Interventions
Control group:Preoperative medication:Aspirin: 300 mg for all patients
P2Y12 inhibitors:
Patients <75 years: Clopidogrel 600 mg?or?Ticagrelor 180 mg or Patients =75 years: Clopidogrel 300 mg.
Intraoperative medication:Heparin: Intravenous injection (100 IU/kg)
High thrombus burden (thrombus score =3):Tirofiban: Initial bolus of 10 µg/kg, followed by continuous intravenous infusion at 0.15 µg/kg/min for 24 hours.Adjusted heparin dose: 50–70 IU/kg.
Long-term
Statins.
Treatment Group:Standard Western medical treatment + Shexiang Baoxin Pills
Shexiang Baoxin Pills administration:Pre-PCI: 90 mg sublingually before percutaneous coronary intervention (PCI).Post-PCI: 45 mg orally three times daily, taken with warm water, for 28 days.
Sponsors
Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Gender and Age: Male or female patients aged >18 years. 2. Diagnosis and Treatment: First-time diagnosis of acute myocardial infarction with persistent chest pain >30 minutes, symptom onset to hospital admission <=12 hours, confirmed by coronary angiography after admission as single-vessel, double-vessel, or triple-vessel disease, and successful completion of PCI. 3. Traditional Chinese Medicine (TCM) Syndrome: Meet the diagnostic criteria for Qi Stagnation and Blood Stasis Syndrome according to TCM guidelines. 4. Comorbidities: Patients with comorbidities (e.g., hypertension, diabetes) are eligible if their conditions are well-controlled by current medications.
Exclusion criteria
Exclusion criteria: 1. Hypersensitivity to Shexiang Baoxin Pills; 2. Comorbidities including rheumatic heart disease, congenital heart disease, valvular heart disease, or idiopathic cardiomyopathy; 3. Post-implantation of cardiac pacemaker or history of previous myocardial infarction; 4. Severe or uncontrolled medical conditions, such as: Severe heart failure (NYHA class III-IV); Severe hepatic or renal insufficiency; Hematological diseases, systemic immune disorders, or active malignant tumors; 5. Acute or recovery-phase conditions: Postoperative recovery period or recovery from major trauma; Active infectious diseases; 6. Pregnancy or lactation: Positive urine pregnancy test; Female patients who are pregnant or lactating; 7. Psychiatric or active infectious diseases.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| GLS; | — |
Secondary
| Measure | Time frame |
|---|---|
| RS;CS;APN;Gal-3;TGF-ß;NT-proBNP;PSD;MWSI;LVEF;LVEDV;LVESV;FS;LTBP4;sST2;TCM Syndrome Score;CRP;IL-6; | — |
Countries
China
Contacts
Public ContactWang Xiaolong
Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine
Outcome results
None listed